MSB mesoblast limited

34.6%

$2.41

Ann: COVID ARDS Trial Topline 60-Day Results, page-1491

First 1491 Last

Share
Profile

Follow
Praetorian2011

2,331 Posts.

389

07/06/21

15:27

Post #: 53694757
Share

Originally posted by RickyH: ↑

I think it is interesting that people think that a partnership with a Big Pharma will be the saviour for this company. I am not so sure Pharma companies are particularly interested in taking this treatment forward.

Stanjupiter commented - 'Any positive findings re. fibrosis will be relevant to sclerodermatous skin GvHD, also a feature of chronic GvHD. You can see on UK Leukemia site, a mother who says her little boy has Jakafi and ECP but still has to use a pusher to get around for longer distances'.
Children are not dying. They are receiving Jakafi. The last thing Novatis wants is for these cells to be approved and their drug profits to be reduced to nil. They will fight any approvals (as we have seen). They will stall any agreement for as long as possible, frustrating shareholders so they sell out, and hopefully bankrupt this company. Pull out of the agreement and the share price drops putting more pressure on the existence of this company. Other cell companies will come along, but one at a time they will attack until their patent runs out.
I am prepared for Novatis is pull out. It's a great strategy on their part to get this IP at a cheap price and bury it for a few years.

How long is a person with cardiac failure kept alive with a truck load of medication? Give the cells and this is no longer necessary? What Pharma company wants this? Particularly those that sell the drugs that are used to slow down the progress of this disease. They do not treat. They slow down the progress. Keep them alive longer so they can take more drugs. What Pharma company wants this to come to an end?

What is Grünenthal doing with regard to lower back pain trial? How far are they along with this? No word. They will stall for as long as possible to keep this 'drug freeing' treatment from the market.

I fell very pessimistic about the progress of cells if we need to rely on Big Pharma for progress. There is very few treatments that cure. They merely treat symptoms. This is my opportunity to back a company that is trying to cure. My shares stay in my hands till the end of this 'war' we are fighting even if I lose every last penny. This is my contribution to a better health future.

Expand

That's a lie mate. Jakafi is banned in Children with GVHD due to toxic side effects. what are you talking about? its not approved, there is no approved RX

MSB Price at posting: $1.78 Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

PSC

Prospect's Mumbezhi Project puts it at the middle of copper's megatrend. And FQM just bought in

AII

A new NASDAQ listing for a key player in the global critical minerals space

BDM

Burgundy plunges -20% after turning to layoffs to navigate record-low diamond prices

DRO

History repeats for DroneShield investors but carnage so far subdued

SYR

Syrah jumps +19% as graphite tariff threat spurs optimism down under

SER

Strategic Energy extends its QLD copper-gold frontier with Diamantina acquisition

HotCopper Highlights: Trigg; Droneshield; Lumos & more

STN

Saturn brings up seventh straight Apollo Hill upgrade on 'impressive' 300-hole drill run

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

Week 29 Wrap: ASX hits new all time high of 8,766pts ahead of Aug 1

First 1491 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.41		Change 0.620(34.6%)		Mkt cap ! $3.084B

Open	High	Low	Value	Volume
$1.90	$2.48	$1.90	$58.82M	25.68M

Buyers (Bids)

No.	Vol.	Price($)
3	100915	$2.40

Sellers (Offers)

Price($)	Vol.	No.
$2.41	99	1

View Market Depth

No.	Vol.	Price($)
2	7415	2.400
4	17144	2.380
1	54202	2.370
2	10040	2.360
4	19500	2.350

Price($)	Vol.	No.
2.410	99	1
2.420	6350	2
2.430	38899	5
2.440	31200	2
2.450	74361	8

Last trade - 16.12pm 18/07/2025 (20 minute delay)

MSB (ASX) Chart

Ann: COVID ARDS Trial Topline 60-Day Results, page-1491

Prospect's Mumbezhi Project puts it at the middle of copper's megatrend. And FQM just bought in

A new NASDAQ listing for a key player in the global critical minerals space

Burgundy plunges -20% after turning to layoffs to navigate record-low diamond prices

History repeats for DroneShield investors but carnage so far subdued

Syrah jumps +19% as graphite tariff threat spurs optimism down under

Strategic Energy extends its QLD copper-gold frontier with Diamantina acquisition

HotCopper Highlights: Trigg; Droneshield; Lumos & more

Saturn brings up seventh straight Apollo Hill upgrade on 'impressive' 300-hole drill run

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

Week 29 Wrap: ASX hits new all time high of 8,766pts ahead of Aug 1

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: COVID ARDS Trial Topline 60-Day Results, page-1491

Top Stories

Prospect's Mumbezhi Project puts it at the middle of copper's megatrend. And FQM just bought in

A new NASDAQ listing for a key player in the global critical minerals space

Burgundy plunges -20% after turning to layoffs to navigate record-low diamond prices

History repeats for DroneShield investors but carnage so far subdued

Syrah jumps +19% as graphite tariff threat spurs optimism down under

Strategic Energy extends its QLD copper-gold frontier with Diamantina acquisition

HotCopper Highlights: Trigg; Droneshield; Lumos & more

Saturn brings up seventh straight Apollo Hill upgrade on 'impressive' 300-hole drill run

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

Week 29 Wrap: ASX hits new all time high of 8,766pts ahead of Aug 1

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News